Display options
Cite
Oh B, Figtree G, Costa D, et al. Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int. 2016;4(3):71-87doi: 10.1016/j.prnil.2016.05.002.
Oh, B., Figtree, G., Costa, D., Eade, T., Hruby, G., Lim, S., Elfiky, A., Martine, N., Rosenthal, D., Clarke, S., & Back, M. (2016). Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate international, 4(3), 71-87. https://doi.org/10.1016/j.prnil.2016.05.002
Oh, Byeongsang, et al. "Oxidative stress in prostate cancer patients: A systematic review of case control studies." Prostate international vol. 4,3 (2016): 71-87. doi: https://doi.org/10.1016/j.prnil.2016.05.002
Oh B, Figtree G, Costa D, Eade T, Hruby G, Lim S, Elfiky A, Martine N, Rosenthal D, Clarke S, Back M. Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int. 2016 Sep;4(3):71-87. doi: 10.1016/j.prnil.2016.05.002. Epub 2016 May 24. PMID: 27689064; PMCID: PMC5031904.
Copy Download .nbib Format: NLM
Share it on

Prostate Int. 2016 Sep;4(3):71-87. doi: 10.1016/j.prnil.2016.05.002. Epub 2016 May 24.

Oxidative stress in prostate cancer patients: A systematic review of case control studies.

Prostate international

Byeongsang Oh, Gemma Figtree, Daniel Costa, Thomas Eade, George Hruby, Stephanie Lim, Aymen Elfiky, Neil Martine, David Rosenthal, Stephen Clarke, Michael Back

Affiliations

  1. Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney Medical School, Sydney, NSW, Australia; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  2. Oxidative Signaling Group, Department of Cardiology, Kolling Institute, University of Sydney, Royal North Shore Hospital, NSW, Australia.
  3. Pain Management Research Institute, University of Sydney, Royal North Shore Hospital, NSW, Australia.
  4. Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney Medical School, Sydney, NSW, Australia.
  5. Department of Medical Oncology, Liverpool Hospital, Ingham Institute for Applied Medical Research, NSW, Australia.
  6. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

PMID: 27689064 PMCID: PMC5031904 DOI: 10.1016/j.prnil.2016.05.002

Abstract

BACKGROUND: Prostate cancer (PCa) is the most common cancer in men in Western countries. In-vitro and in-vivo studies suggest that oxidative stress (OS) and antioxidants play a key role in the pathogenesis of chronic diseases including PCa, which is promoted by the production of reactive oxygen species and impaired antioxidant defense mechanisms. This study evaluates the association between OS and men with PCa.

METHODS: A literature search was carried out on Medline, PubMed, and ScienceDirect databases, as well as manual searches from inception up to August 2015 using the keywords "Oxidative stress" or "Reactive oxygen species" or "Lipid peroxidation" AND "Prostate cancer." All studies including data on the measurement of OS biomarkers in PCa were included.

RESULTS: Twenty-three case control studies were retrieved with sample sizes ranging from 15 to 3,613 (6,439 participants in total). Markers of OS were significantly higher in patients with PCa compared with control groups in 21 studies. Two self-controlled case studies comparing OS between PCa cells and non-PCa cells in tissue biopsies found OS to be statistically higher in PCa cancer cells. Results on markers of antioxidant capacity (superoxide dismutase, catalase, glutathione, glutathione reductase, glutathione peroxidase, uric acid, lutein, lycopene, beta carotein, vitamin A, vitamin C, vitamin E, and total antioxidants) were not completely consistent in their association with PCa.

CONCLUSIONS: Upregulated OS profiles and impairment of antioxidant defense systems may play a role in men with PCa. To confirm these findings, robust clinical trials utilizing a personalized approach which monitors both OS and antioxidant markers during therapy are warranted.

Keywords: Antioxidant; Oxidative stress; Peroxidation; Prostate cancer; Reactive oxygen species

References

  1. Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):262-71 - PubMed
  2. CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40 - PubMed
  3. Mol Cell Biochem. 2013 Jan;372(1-2):149-53 - PubMed
  4. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1536-9 - PubMed
  5. Indian J Clin Biochem. 2005 Jul;20(2):162-5 - PubMed
  6. PLoS One. 2015 Sep 15;10(9):e0137427 - PubMed
  7. JAMA. 2009 Jan 7;301(1):52-62 - PubMed
  8. Oxid Med Cell Longev. 2012;2012:789870 - PubMed
  9. Mol Cell Biochem. 2004 Nov;266(1-2):37-56 - PubMed
  10. Cancer Lett. 1997 Oct 28;119(1):13-9 - PubMed
  11. Clin Biochem. 2009 Aug;42(12):1228-35 - PubMed
  12. Cancer. 1998 May 15;82(10):1897-903 - PubMed
  13. Clin Chem Lab Med. 2006;44(2):175-9 - PubMed
  14. Biochem Pharmacol. 2012 Apr 15;83(8):1005-12 - PubMed
  15. N Engl J Med. 1994 Apr 14;330(15):1029-35 - PubMed
  16. Biomed Pharmacother. 2011 Oct;65(7):516-24 - PubMed
  17. Clin Genitourin Cancer. 2015 Oct;13(5):e347-51 - PubMed
  18. BJU Int. 2001 Jul;88(1):100-3 - PubMed
  19. Eur Heart J. 2015 Jul 1;36(25):1576-82, 1582a-b - PubMed
  20. Urol Oncol. 2013 Nov;31(8):1561-6 - PubMed
  21. Int Urol Nephrol. 2004;36(1):57-62 - PubMed
  22. Cancer Prev Res (Phila). 2010 Apr;3(4):478-83 - PubMed
  23. J Clin Oncol. 2005 Aug 20;23(24):5805-13 - PubMed
  24. Cancer Lett. 2005 Sep 28;227(2):133-9 - PubMed
  25. Biochim Biophys Acta. 2009 Apr;1795(2):83-91 - PubMed
  26. Tumour Biol. 2014 May;35(5):4295-9 - PubMed
  27. Lancet. 2003 Mar 8;361(9360):859-64 - PubMed
  28. J Clin Oncol. 2007 Apr 20;25(12):1596-605 - PubMed
  29. Prostate. 2004 Dec 1;61(4):318-23 - PubMed
  30. Cell Biochem Funct. 2007 Jul-Aug;25(4):377-82 - PubMed
  31. Acc Chem Res. 2011 Jun 21;44(6):458-67 - PubMed
  32. Carcinogenesis. 2006 Jun;27(6):1187-93 - PubMed
  33. Free Radic Biol Med. 2010 Dec 1;49(11):1603-16 - PubMed
  34. Cancer Res. 2001 Aug 15;61(16):6025-8 - PubMed
  35. Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1430-8 - PubMed
  36. J Urol. 2012 Jun;187(6):2005-10 - PubMed
  37. J Lipid Res. 2013 Mar;54(3):852-8 - PubMed
  38. Biol Trace Elem Res. 2004 Apr;98(1):13-19 - PubMed
  39. Exp Oncol. 2008 Sep;30(3):244-7 - PubMed
  40. J Natl Cancer Inst. 2001 Dec 19;93(24):1872-9 - PubMed
  41. BMJ Open. 2012 Jul 31;2(4):null - PubMed
  42. Cancer Lett. 2009 Sep 18;282(2):125-36 - PubMed
  43. Int J Cancer. 2006 Feb 15;118(4):1051-3 - PubMed
  44. Oncogene. 2003 Oct 20;22(47):7369-75 - PubMed
  45. Res Rep Urol. 2014 Aug 16;6:107-12 - PubMed
  46. J Urol. 2007 Oct;178(4 Pt 1):1238-43; discussion 1243-4 - PubMed
  47. Oxid Med Cell Longev. 2010 Jul-Aug;3(4):228-37 - PubMed
  48. J Urol. 2011 Jun;185(6):2102-7 - PubMed
  49. Am J Clin Nutr. 2004 Jun;79(6):1029-36 - PubMed
  50. Singapore Med J. 2008 Aug;49(8):640-3 - PubMed
  51. Prostate. 2008 Jun 15;68(9):924-34 - PubMed
  52. Clin Biochem. 2006 Feb;39(2):176-9 - PubMed
  53. Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):161-6 - PubMed
  54. Cancer Causes Control. 2000 Mar;11(3):197-205 - PubMed
  55. Pol Arch Med Wewn. 2009 Sep;119(9):526-32 - PubMed
  56. J Natl Cancer Inst. 1997 Jan 1;89(1):40-8 - PubMed
  57. JAMA. 2009 Jan 7;301(1):39-51 - PubMed
  58. Int J Neurosci. 2006 Aug;116(8):937-43 - PubMed
  59. Ann Clin Lab Sci. 2012 Winter;42(1):94-7 - PubMed
  60. Breast Cancer Res Treat. 2009 Jun;115(3):437-52 - PubMed
  61. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009 Apr;27(2):120-39 - PubMed
  62. Redox Biol. 2013 Feb 08;1:244-57 - PubMed
  63. Pak J Med Sci. 2014 May;30(3):466-71 - PubMed
  64. J Urol. 2004 Apr;171(4):1533-6 - PubMed
  65. Indian J Physiol Pharmacol. 2006 Oct-Dec;50(4):350-4 - PubMed
  66. J Clin Epidemiol. 2013 Sep;66(9):982-93 - PubMed
  67. Eur J Epidemiol. 2010 Sep;25(9):603-5 - PubMed

Publication Types